TrialCardiovascular diabetology2022

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).

Massar Omar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.